68 countries. The Gamaleya National Center of Epidemiology and Microbiology in Moscow, Russia, developed the vaccine.Sputnik V is a viral vector vaccine designed to produce lasting immunity against COVID-19.
According to an interim analysis of phase 3 clinical trial data published in The Lancet, the vaccine’s efficacy is 91.6%. However, a number of scientists have publicly called into question the results from the phase 1/2 and phase 3 trials.
A viral vector is a harmless virus that can deliver a gene to our cells that they turn into a protein. Scientists have studied the use of viral vectors for gene therapy and vaccines.